Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine - Poll - MDSpire

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • By

  • Spyros Chalkias

  • Antionette Pragalos

  • Adebayo Akinsola

  • Gary Berman

  • Madhavi Ampajwala

  • Jay Meyer

  • Lorraine Schoch

  • Wen Zhou

  • Yamuna D Paila

  • Weiping Deng

  • Jing Feng

  • Elizabeth de Windt

  • Darin Edwards

  • Jacqueline Miller

  • Rituparna Das

  • January 10, 2025

  • 0 min

Share

Original Source(s)

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • by Spyros Chalkias, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay Meyer, Lorraine Schoch, Wen Zhou, Yamuna D Paila, Weiping Deng, Jing Feng, Elizabeth de Windt, Darin Edwards, Jacqueline Miller, Rituparna Das

  • January 10, 2025

Related Content

Effectiveness of Telemedicine vs Face-to-Face Consultation in Fighting COVID-19: Retrospective Cohort Study of Adult Patients With COVID-19 in a Primary Care Setting

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.